Biogen, a biotechnology company specializing in therapies for neurodegenerative diseases, and certain of the company's executives were hit with a securities class action Monday in Massachusetts District Court. The lawsuit, brought by Block & Leviton, accuses the defendants of engaging in back-channel meetings with FDA officials in an effort to gain approval for Biogen's Alzheimer's treatment Aduhelm. The complaint asserts that the irregular discussions are being investigated by the federal government. Counsel have not yet appeared for the defendants. The case is 1:22-cv-10200, Oklahoma Firefighters Pension and Retirement System v. Biogen Inc. et al.
Biotech & Pharmaceuticals
February 07, 2022, 6:14 PM